After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
Starglo isn't applicable to a US population, an adcom rules.
PF-08046037 joins PF-08046054 in clinical development.
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
